Booster dose of Pfizer’s COVID-19 vaccine neutralizes Omicron variant, company says
Global News
BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralizing antibodies but that a third dose of their vaccine increased the neutralizing antibodies
BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and they could deliver an Omicron-based vaccine in March 2022 if needed.
In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralizing antibodies but that a third dose of their vaccine increased the neutralizing antibodies by a factor of 25.
Blood obtained from people that had their third booster shot a month ago neutralized the Omicron variant about as effectively as blood after two doses fought off the original virus first identified in China.
“Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19,” Pfizer boss Albert Bourla said in the statement.
Though the necessity remains unclear, the companies said they would continue their effort to bring an Omicron-specific COVID-19 vaccine to market, which they kick-started when the new lineage first raised global concern among scientists on Nov. 25.
A planned output of 4 billion doses of the Comirnaty vaccine in 2022 was not expected to change if an adapted vaccine was required, they added.
The findings are broadly in line with a preliminary study published by researchers at the Africa Health Research Institute in South Africa on Tuesday, saying that Omicron can partially evade protection from two doses of the Pfizer/BioNTech vaccine, suggesting also that a third shot might help fend off infection.
A lab analysis at the university hospital of Frankfurt, Germany, however found a reduced antibody response to Omicron even after three shots.
In the week ending Dec. 20, one in four (25.6 per cent) of every influenza test conducted in the U.S. came back positive, the U.S. CDC said.
As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.
The B.C. Ministry of Transportation says Highway 16 linking Prince Rupert to communities in the east including Terrace has been shut in both directions due to flooding.
Time blindness has sparked a social media debate: Where is the line between a genuine condition and someone who is disorganized or just plain rude?